Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.
Friedman GK, Johnston JM, Bag AK, Bernstock JD, Li R, Aban I, Kachurak K, Nan L, Kang KD, Totsch S, Schlappi C, Martin AM, Pastakia D, McNall-Knapp R, Farouk Sait S, Khakoo Y, Karajannis MA, Woodling K, Palmer JD, Osorio DS, Leonard J, Abdelbaki MS, Madan-Swain A, Atkinson TP, Whitley RJ, Fiveash JB, Markert JM, Gillespie GY. Friedman GK, et al. Among authors: kachurak k. N Engl J Med. 2021 Apr 29;384(17):1613-1622. doi: 10.1056/NEJMoa2024947. Epub 2021 Apr 10. N Engl J Med. 2021. PMID: 33838625 Free PMC article.
Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.
Waters AM, Johnston JM, Reddy AT, Fiveash J, Madan-Swain A, Kachurak K, Bag AK, Gillespie GY, Markert JM, Friedman GK. Waters AM, et al. Among authors: kachurak k. Hum Gene Ther Clin Dev. 2017 Mar;28(1):7-16. doi: 10.1089/humc.2017.002. Hum Gene Ther Clin Dev. 2017. PMID: 28319448 Free PMC article. Clinical Trial.
Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
Bernstock JD, Bag AK, Fiveash J, Kachurak K, Elsayed G, Chagoya G, Gessler F, Valdes PA, Madan-Swain A, Whitley R, Markert JM, Gillespie GY, Johnston JM, Friedman GK. Bernstock JD, et al. Among authors: kachurak k. Hum Gene Ther. 2020 Oct;31(19-20):1132-1139. doi: 10.1089/hum.2020.101. Epub 2020 Aug 17. Hum Gene Ther. 2020. PMID: 32657154 Free PMC article.
A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition.
Bernstock JD, Vicario N, Rong L, Valdes PA, Choi BD, Chen JA, DiToro D, Osorio DS, Kachurak K, Gessler F, Johnston JM Jr, Atkinson TP, Whitley RJ, Bag AK, Gillespie GY, Markert JM, Maric D, Friedman GK. Bernstock JD, et al. Among authors: kachurak k. Oncoimmunology. 2019 Oct 21;8(12):e1678921. doi: 10.1080/2162402X.2019.1678921. eCollection 2019. Oncoimmunology. 2019. PMID: 31741780 Free PMC article.
Clinical advances in oncolytic virotherapy for pediatric brain tumors.
Ghajar-Rahimi G, Kang KD, Totsch SK, Gary S, Rocco A, Blitz S, Kachurak K, Chambers MR, Li R, Beierle EA, Bag A, Johnston JM, Markert JM, Bernstock JD, Friedman GK. Ghajar-Rahimi G, et al. Among authors: kachurak k. Pharmacol Ther. 2022 Nov;239:108193. doi: 10.1016/j.pharmthera.2022.108193. Epub 2022 Apr 26. Pharmacol Ther. 2022. PMID: 35487285 Free PMC article. Review.
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.
Rosenberg T, Yeo KK, Mauguen A, Alexandrescu S, Prabhu SP, Tsai JW, Malinowski S, Joshirao M, Parikh K, Farouk Sait S, Rosenblum MK, Benhamida JK, Michaiel G, Tran HN, Dahiya S, Kachurak K, Friedman GK, Krystal JI, Huang MA, Margol AS, Wright KD, Aguilera D, MacDonald TJ, Chi SN, Karajannis MA. Rosenberg T, et al. Among authors: kachurak k. Neuro Oncol. 2022 Nov 2;24(11):1964-1975. doi: 10.1093/neuonc/noac096. Neuro Oncol. 2022. PMID: 35397478 Free PMC article.